These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1663475)

  • 1. Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate.
    Bang CJ; Berstad A; Talstad I
    Haemostasis; 1991; 21(3):155-60. PubMed ID: 1663475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
    Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
    Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice.
    Bernat A; Hoffmann P; Herbert JM
    Thromb Haemost; 1996 Nov; 76(5):715-9. PubMed ID: 8950779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats.
    Bang CJ; Berstad A; Talstad I
    Haemostasis; 1991; 21(1):30-6. PubMed ID: 1650745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protamine reversal of low molecular weight heparin: clinically effective?
    van Veen JJ; Maclean RM; Hampton KK; Laidlaw S; Kitchen S; Toth P; Makris M
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):565-70. PubMed ID: 21959588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice.
    Swieton J; Miklosz J; Yusa SI; Szczubialka K; Pawlak D; Mogielnicki A; Kalaska B
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of heparin and LMW heparin on hemostasis.
    Hirsh J; Buchanan MR
    Thromb Res Suppl; 1991; 14():11-7. PubMed ID: 1658966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
    Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
    J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine.
    Dietrich CP; Shinjo SK; Moraes FA; Castro RA; Mendes A; Gouvea TC; Nader HB
    Semin Thromb Hemost; 1999; 25 Suppl 3():43-50. PubMed ID: 10549715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protamine sulphate inhibits pentasaccharide (SR80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat.
    Bernat A; Herbert JM
    Haemostasis; 1996; 26(4):195-202. PubMed ID: 8872130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding effects of unfractionated heparin and low molecular weight heparins in an animal model.
    Bang CJ; Talstad I; Berstad A
    Eur J Surg Suppl; 1994; (571):23-9. PubMed ID: 7519085
    [No Abstract]   [Full Text] [Related]  

  • 13. Protamine sulfate for the reversal of enoxaparin associated hemorrhage beyond 12 h.
    Lauer BR; Nelson RA; Adamski JH; Gibbons J; Janko MR; Ravi G; Barcelona RA
    Am J Emerg Med; 2019 Jan; 37(1):174.e5-174.e6. PubMed ID: 30274763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans.
    Bang CJ; Riedel B; Talstad I; Berstad A
    Scand J Gastroenterol; 1992 Jun; 27(6):489-94. PubMed ID: 1321488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine.
    Racanelli A; Fareed J
    Thromb Res; 1992 Jul; 67(2):263-73. PubMed ID: 1332215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content.
    Chawla LS; Moore G; Seneff MG
    Obes Surg; 2004 May; 14(5):695-8. PubMed ID: 15186641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.
    Torjemane L; Guermazi S; Ladeb S; Ben Romdhane N; Lakhal A; Abdelkefi A; Ben Othman T; Ben Abdelhadhim A
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):279-81. PubMed ID: 17413766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
    Diness V; Ostergaard PB
    Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric mucosal bleeding after unfractionated and low molecular weight heparin in rats.
    Bang CJ; Berstad A; Talstad I
    Scand J Gastroenterol; 1990 Apr; 25(4):379-82. PubMed ID: 2159654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The toxicology of heparin reversal with protamine: past, present and future.
    Sokolowska E; Kalaska B; Miklosz J; Mogielnicki A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):897-909. PubMed ID: 27223896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.